1. Market Research
  2. > Life Sciences Market Trends
LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035

LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035

  • April 2020
  • 80 pages
  • ID: 5879439
  • Format: PDF
  • Delve Insight
Up to $2370 off Until Dec 10th 2020


Table of Contents

‘LAG-3-Next Generation Immunotherapy—Competitive Landscape and Market Forecast–2035’ report delivers an in-depth understanding of the LAG-3 as well as the market trends of LAG-3-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The report provides the upcoming drugs, market share of this target by indications, forecasted market size of LAG-3-Next Generation Immunotherapy from 2022 to 2035 segmented by seven major markets. This report discusses the recent findings on LAG-3, the role it plays in regulating immune responses in different cell types and the rationale for targeting LAG-3 for effective cancer immunotherapy. The report also covers the current scenario, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2022–2035

LAG-3-Next Generation Immunotherapy Understanding
Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the “fifth pillar” of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 have achieved durable responses in melanoma, renal cancer, Hodgkin’s diseases and lung cancer. However, the success rate of these treatments has been low and a large number of cancers, including colorectal cancer remain largely refractory to CTLA-4 and PD-1 blockade.
Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. T cells are a type of white blood cell that are part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1. It acts by regulating CD8+ Tcell expansion in immune reactions that have already been initiated (inhibitory signal) and also, by increasing the Treg cell activity.
The inhibitory immune checkpoint lymphocyte activation gene-3 (LAG-3) holds considerable potential. LAG-3 suppresses T cells activation and cytokines secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses. Targeting LAG-3 immunotherapy is moving forward in active clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance. Herein, we shed light on the significance of LAG-3 in the tumor microenvironment, highlight its role to regulate different lymphocytes, interplay with other immune checkpoints especially PD-1, and emphasize new advances in LAG-3-targeted immunotherapy.
LAG-3 structure
LAG-3 is a transmembrane protein with structural homology to CD4, in which it includes four extracellular IgG domains. The membrane-distal IgG domain contains a short amino acid sequence, the so-called extra loop that is not found in other IgG superfamily proteins. The intracellular domain contains a unique amino acid sequence (KIEELE) that is required for LAG-3 to exert a negative effect on T cell function. LAG-3 can be cleaved at the connecting peptide (CP) by metalloproteases to generate a soluble form, which is detectable in serum
LAG-3 and Immune Function
After a T cell is activated to kill its target cell, LAG-3 expression is increased to turn off the immune response, so that the T cell does not go on to attack healthy cells. Inhibition of the immune response is accomplished through the binding of LAG-3 to an antigen-presenting complex called MHC II, which together signal the T cell to stop activation and multiplication.
LAG-3 and T Cell Exhaustion
However, in certain situations where T cells experience prolonged exposure to an antigen, such as cancer or chronic infection, the T cells become desensitized and lose their ability to activate and multiply in the presence of the antigen.
Interactions with Other Pathways
Preclinical studies suggest that targeting the LAG-3 pathway in combination with other potentially complementary immune pathways may be a key strategy to more effectively activate the antitumor immune response.
Role Of LAG-3 in Autoimmune Disorders
Beyond the inhibitory activity of LAG-3 on different types of lymphocytes, LAG-3 may also be necessary to negativelyregulate autoimmunity in many disease-prone environments. For instance, loss of LAG-3 substantially can accelerate type 1 diabetes in Non-Obese Diabetic (NOD) mice with 100% incidence. LAG-3 deficient mice can exhibit increased antigen-reactive CD4+ and CD8+ T cells infiltration in the islets, accompanied by invasive and rapid insulitis.
LAG-3 in Cancer Immunotherapy
LAG-3 (CD223) is a cell surface molecule expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function. Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients.

LAG-3-Next Generation Immunotherapy Drug Chapters
This segment of the LAG-3-Next Generation Immunotherapy report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the indication-specific clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.
The major key players such as MacroGenics/Zai Lab, Bristol-Myers Squibb/Ono Pharmaceuticals, Immutep, Novartis, Merck, F-star Therapeutics, Regeneron, Xencor, Incyte Biosciences/Agenus, Roche, GlaxoSmithKline, Innovent Biologics (Suzhou) Co. Ltd. and others will significantly increase the market during the forecast period (2022–2035).
The expected launch of emerging therapies, such as MGD013, Relatlimab, Eftilagimod Alpha (IMP321), LAG525, MK-4280, FS118, REGN3767, XmAb22841, INCAGN2385, RO7247669, TSR-033, IBI110 and other treatments, would lead to a significant increase in the market size during the forecast period (2022–2035).

LAG-3-Next Generation Immunotherapy Emerging Drugs
MGD013: MacroGenics
MGD013 which is being developed by MacroGenics is an IgG4? bispecific DART molecule that binds to PD-1 and LAG-3 concomitantly or independently and disrupts non-redundant inhibitory pathways to restore shattered T-cell function further. The drug is the first in a series of product candidates that distinguish in the multiple immune regulatory targets. The drug is currently being evaluated in a phase II/III study in which the dose and schedule have been established and dose-expansion has been initiated in up to nine tumor types.
LAG525: Novartis
LAG525 (anti-LAG-3, also known as IMP701) which is under development by Novartis is an investigational immunotherapy being developed to potentially treat a range of solid tumors. The drug is a humanized form of IMP701 is currently being evaluated in five phase I and phase II clinical trials in combination with Novartis’ PD-1 inhibitor spartalizumab for the treatment of various cancers.

Relatlimab (BMS-986016): Bristol-Myers Squibb

Relatlimab (previously known as BMS-986016) is a cancer immunotherapy being developed by Bristol-Myers Squibb (BMS). The treatment has already shown benefit in melanoma patients and is also being tested in other cancers. Immunotherapies use the body’s own immune system to fight cancer, instead of directly attacking cancer cells.

Eftilagimod Alpha (IMP321): Immutep
Eftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to induce sustained immune responses. Combining active immunotherapy with a standard cytotoxic chemotherapy regimen represents a promising novel strategy that might lead to therapeutic improvements in metastatic breast cancer.

MK-4280: Merck
A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-LAG3 monoclonal antibody MK-4280 binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T cells. Its expression on TILs is associated with tumor-mediated immune suppression.

Further drug information is provided in the detailed report

LAG-3-Next Generation Immunotherapy Market Outlook
The LAG-3-Next Generation Immunotherapy market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of LAG-3-Next Generation Immunotherapy market trend of each late-stage pipeline therapy by evaluating their impact based on the annual cost of treatment, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.
According to the report, the LAG-3-Next Generation Immunotherapy market is expected to generate USD 3,421 Million in the year 2035 with a significant CAGR in the forecast period (2022?2035).

Key Findings
• According to the analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022–2035).

• According to the analysis, NSCLC will occupy the major market share that is 98.81% by 2035. Also, the total market size for LAG-3 by indications is expected to be USD 3,421 Million by 2035.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working for third-generation immunotherapies in various indications through primary research to fill the data gaps and validate our secondary research. Their opinion helps us to understand and verify current and emerging therapies treatment patterns or current market trends. It will also support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the LAG-3-Next Generation Immunotherapy market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the availability of the data.

Scope of the report
• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.
• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.

Report Highlights
• In the coming years, LAG-3-Next Generation Immunotherapy market is set to change due to the Addition of new emerging technologies for the development of targeted therapies, personalized drug therapies with combinational therapies to enhance the efficacy, Increasing funding for R&D expense; which would expand the market size to enable the drug manufacturers to penetrate more into the market.
• The companies and researchers are working to overcome the challenges and seek opportunities that could help them to develop specific therapies for the treatment of various indications by using LAG-3-Next Generation Immunotherapy. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Launch of emerging therapies will significantly impact the LAG-3-Next Generation Immunotherapy market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for the LAG-3-Next Generation Immunotherapy market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
LAG-3-Next Generation Immunotherapy Report Insights
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming therapies

LAG-3-Next Generation Immunotherapy Report Key Strengths
• 14-Year Forecast
• 7MM Coverage

• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
• Market Size by Country
• Market Size by Therapy

LAG-3-Next Generation Immunotherapy Report Assessment
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
• Competitive Intensity of LAG-3-Next Generation Immunotherapy
• Market Competition of LAG-3-Next Generation Immunotherapy
• Technological innovations in LAG-3-Next Generation Immunotherapy
• Multivariate analysis of the key players in the LAG-3-Next Generation Immunotherapy
• Pipeline Therapeutics
• Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy
• SWOT Analysis
• Assessment by Product Type
• Assessment by Stage Type
• Assessment by Route of Administration
• Comparative Analysis

Key Questions
• What was the LAG-3-Next Generation Immunotherapy Market share (%) distribution in 2022, and how would it look like in 2035?
• What would be the LAG-3-Next Generation Immunotherapy total market size as well as market size by indications across the 7MM during the forecast period (2022?2035)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest LAG-3-Next Generation Immunotherapy market size during the forecast period (2022?2035)?
• At what CAGR, the LAG-3-Next Generation Immunotherapy market is expected to grow in 7MM during the forecast period (2022?2035)?
• What would be the LAG-3-Next Generation Immunotherapy market outlook across the 7MM during the forecast period (2022?2035)?
• What would be the LAG-3-Next Generation Immunotherapy market growth till 2035, and what will be the resultant market size in the year 2035?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• How does the market size look like for the market size by indications for each 7MM? And what is the revenue this treatment option expected to garner in the various indications?
• Where the emerging therapies are focusing more?
Reason to buy
• This report will help to develop Business Strategies by understanding the trends shaping and driving the LAG-3-Next Generation Immunotherapy market
• Organize sales and marketing efforts by identifying the best opportunities for LAG-3-Next Generation Immunotherapy market
• To understand the future market competition in the LAG-3-Next Generation Immunotherapy market and Insightful review of the key market drivers and barriers.
• Identification of strong upcoming players in the market will help in planning strategies that will help in getting ahead of competitors.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

2020-2025 Italy Hematology and Flow Cytometry Database: Analyzers and Reagents, Supplier Shares, Test Volume and Sales Segment Forecasts

  • $ 2500
  • November 2020
  • 1 pages

2020-2025 Italy Hematology and Flow Cytometry Database: Analyzers and Reagents, Supplier Shares, Test Volume and Sales Segment Forecasts This database provides the 2020 supplier shares, the 2020-2025 ...

  • Italy
  • Molecular Diagnostics
  • In Vitro Diagnostic Reagent
  • Industry analysis


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on